Navigation Links
Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
Date:9/22/2007

ENGLEWOOD, Colo., Sept. 21 /PRNewswire/ -- Baxa Corporation, a leading provider of systems for safe fluid handling and delivery in hospital pharmacies, announces the addition of two new international product distributors. These agreements -- with Magallan Pharma Trading Corporation in Colombia and Pentafarma & Co. in The Dominican Republic -- will enable Baxa to extend its global reach and expand product promotion in South America and the Caribbean.

"Global markets offer significant potential for growth in Baxa Corporation's key product lines," says Steve Welch, VP of New Business Development. "These new partnerships expand the visibility of the Baxa brand and give us opportunities for sales growth and market expansion. With their focus on pharmacy efficiency and patient safety, Baxa products offer a unique value in healthcare worldwide."

Baxa Corporation provides distributor training and technical support at its headquarters in Englewood, Colorado. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada and the United Kingdom; direct representation in Austria, Belgium, Finland, France, Germany, Luxembourg, The Netherlands and Switzerland; and distribution partners in 35 other countries worldwide.

About Baxa Corporation

Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for fluid handling and delivery. Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of fluid medications. Key products include Rapid-Fill(TM) Automated Syringe Fillers, Exacta-Med(R) Oral Dispensers, MicroFuse(R) Syringe Infusers, Repeater(TM) Pharmacy Pumps, and Exacta-Mix(TM) and MicroMacro(TM) Multi-Source Automated Compounders; used worldwide in hospitals and healthcare facilities -- http://www.baxa.com.

About Magallan Pharma Trading

Magallan is a newly formed company within a group of companies serving the healthcare industry in Colombia. 'Salud Total,' overseeing Magallan, is the third largest health services company in Colombia. Magallan is responsible for location of needed products, Colombian registration with the Health authorities and product distribution.

About Pentafarma CxA

Pentafarma is a pharmaceutical and medical device distributor in the Dominican Republic selling supplies to hospitals in that country. Clients include oncology and gynecological hospitals and surgery centers.

Contact:

Marian Robinson, Vice President, Marketing

Baxa Corporation: 800.567.2292 ext. 2157 or 303.617.2157

Email: marian.robinson@baxa.com

Maggie Chamberlin Holben, APR

Absolutely Public Relations: 303.984.9801 or 303.669.3558

Email: maggie@absolutelypr.com

Luis Jimenez

Magallan Pharma Trading Corp: 57-12-55-9945

Email: luis.jimenez@magallanpharmatrading.com

Leida Perez

Pentafarma & Co. CXA:

809-227-0322

Fax; 809-563-5143

Email; lperez@pentafarma.net


'/>"/>
SOURCE Baxa Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
3. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
4. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
5. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
6. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
7. MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone
8. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
9. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
10. New Study Reveals Limitations of a Complex and Challenging Global Tuberculosis Drug Marketplace
11. Global Rabies Treatment May be Possible with NanoViricides Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/10/2019)... (PRWEB) , ... January 10, 2019 , ... ... to introduce the new A-Series Advantage Anesthesia Delivery platform, providing a modular, state-of-the-art ... A7 Advantage systems, enabling Mindray to continue its unwavering commitment to perioperative care. ...
(Date:1/8/2019)... , ... January 08, 2019 , ... ... been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. ... System and demonstrated a commitment to exemplary care for men suffering from symptoms ...
(Date:1/8/2019)... ... January 08, 2019 , ... “A baby is born ... can change that alarming statistic,” said Christina Chambers, PhD, MPH, President of MotherToBaby, ... is joining with leading prenatal health experts from the National Birth Defects Prevention ...
Breaking Medicine Technology:
(Date:1/15/2019)... ... January 15, 2019 , ... Ophthalmic Consultants of Long ... office to a new, larger space at 70 East Sunrise Highway, Suite 400, Valley ... needs of its patients. , According to Gerard D’Aversa, MD, “After serving the Valley ...
(Date:1/14/2019)... ... , ... After many months of preparation, the providers and staff at San ... Asthma. This new allergy and asthma clinic is conveniently located in the heart of ... any immunological and respiratory medical care needs. , In the new allergy and asthma ...
(Date:1/14/2019)... ... January 14, 2019 , ... Yes, the Millennials love their Bluetooth ... Council on Active Aging® (ICAA), new tech is also finding a home in senior ... , queried respondents from a variety of organizations that work with older adults about ...
(Date:1/14/2019)... ... January 15, 2019 , ... Early bird pricing for Medical Device Risk ... is just plain hard, complicated, conflicted, confusing. And it is getting even more complicated ... not intended as “major”, the new standard adds new definitions, changes the clause numbering, ...
(Date:1/14/2019)... ... January 14, 2019 , ... ... and availability of VARIZIG® (Varicella Zoster Immune Globulin [Human]) for post-exposure prophylaxis ... In the update, the CDC notes that VARIZIG is commercially available from a ...
Breaking Medicine News(10 mins):